Thiol-based antioxidant supplementation alters human skeletal muscle signaling and attenuates its inflammatory response and recovery after intense eccentric exercise

Am J Clin Nutr. 2013 Jul;98(1):233-45. doi: 10.3945/ajcn.112.049163. Epub 2013 May 29.

Abstract

Background: The major thiol-disulfide couple of reduced glutathione (GSH) and oxidized glutathione is a key regulator of major transcriptional pathways regulating aseptic inflammation and recovery of skeletal muscle after aseptic injury. Antioxidant supplementation may hamper exercise-induced cellular adaptations.

Objective: The objective was to examine how thiol-based antioxidant supplementation affects skeletal muscle's performance and redox-sensitive signaling during the inflammatory and repair phases associated with exercise-induced microtrauma.

Design: In a double-blind, crossover design, 10 men received placebo or N-acetylcysteine (NAC; 20 mg · kg(-1) · d(-1)) after muscle-damaging exercise (300 eccentric contractions). In each trial, muscle performance was measured at baseline, after exercise, 2 h after exercise, and daily for 8 consecutive days. Muscle biopsy samples from vastus lateralis and blood samples were collected before exercise and 2 h, 2 d, and 8 d after exercise.

Results: NAC attenuated the elevation of inflammatory markers of muscle damage (creatine kinase activity, C-reactive protein, proinflammatory cytokines), nuclear factor κB phosphorylation, and the decrease in strength during the first 2 d of recovery. NAC also blunted the increase in phosphorylation of protein kinase B, mammalian target of rapamycin, p70 ribosomal S6 kinase, ribosomal protein S6, and mitogen activated protein kinase p38 at 2 and 8 d after exercise. NAC also abolished the increase in myogenic determination factor and reduced tumor necrosis factor-α 8 d after exercise. Performance was completely recovered only in the placebo group.

Conclusion: Although thiol-based antioxidant supplementation enhances GSH availability in skeletal muscle, it disrupts the skeletal muscle inflammatory response and repair capability, potentially because of a blunted activation of redox-sensitive signaling pathways. This trial was registered at clinicaltrials.gov as NCT01778309.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcysteine / administration & dosage
  • Adaptation, Physiological / drug effects
  • Adult
  • Antioxidants / administration & dosage*
  • Biomarkers / blood
  • C-Reactive Protein / metabolism
  • Creatine Kinase / metabolism
  • Cross-Over Studies
  • Cytokines / metabolism
  • Diet
  • Dietary Supplements*
  • Double-Blind Method
  • Exercise / physiology*
  • Glutathione / metabolism
  • Humans
  • Immunohistochemistry
  • Inflammation / drug therapy
  • Male
  • Muscle Contraction / drug effects
  • NF-kappa B / metabolism
  • Phosphorylation
  • Proto-Oncogene Proteins c-akt / metabolism
  • Quadriceps Muscle / drug effects*
  • Quadriceps Muscle / metabolism
  • Quadriceps Muscle / physiology
  • Ribosomal Protein S6 / metabolism
  • Ribosomal Protein S6 Kinases, 70-kDa / metabolism
  • Signal Transduction / drug effects
  • Sulfhydryl Compounds / administration & dosage*
  • Tumor Necrosis Factor-alpha / metabolism
  • Young Adult
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • Antioxidants
  • Biomarkers
  • Cytokines
  • NF-kappa B
  • Ribosomal Protein S6
  • Sulfhydryl Compounds
  • Tumor Necrosis Factor-alpha
  • C-Reactive Protein
  • Proto-Oncogene Proteins c-akt
  • Ribosomal Protein S6 Kinases, 70-kDa
  • p38 Mitogen-Activated Protein Kinases
  • Creatine Kinase
  • Glutathione
  • Acetylcysteine

Associated data

  • ClinicalTrials.gov/NCT01778309